Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by longterm56on Jun 22, 2021 11:21pm
152 Views
Post# 33432431

RE:RE:RE:RE:RE:RE:RE:Weekly Report Card

RE:RE:RE:RE:RE:RE:RE:Weekly Report CardWell, according to SPCEO (below), we can now be pessimistic.  I'm starting to think the market has it correct, just like they had it correct from May 2018 on during "the big slide". It seems very unlikely that the experts (and big pharma) are not aware of this work, it's been presented at several conferences. A more realistic explanation is that there is something they see that gives it little value. 

Starting to lose the faith ...

  -LT 



SPCEO1 wrote: < clip > If the company shares good news about cancer and the market does not react to that, particulalrly with LSA helping spread that news to investors who may not be very familiar with TH, then you can be pessimistic. But that is unlikely to be the outcome.

Bucknelly21 wrote: I have a very hard time seeing the lsa event turning around this dismal sp th is in no mans land 




<< Previous
Bullboard Posts
Next >>